ErVimmune secures €17 million in Series A funding to advance its cancer vaccine, ErVac01, targeting cold tumors with a unique approach using human endogenous retrovirus-derived antigens.

Target Company Overview

ErVimmune is a pioneering biotechnology firm based in Lyon, France, that specializes in the development of next-generation therapeutic vaccines intended to combat cancer. Founded in October 2019 by Prof. Stéphane Depil, a prominent onco-hematologist, the company is a spin-off from the Centre Léon Bérard and focuses primarily on innovative cancer treatments targeting unconventional tumor antigens derived from human endogenous retroviruses (HERVs). The company’s lead candidate, ErVac01, aims to address significant unmet medical needs associated with 'cold tumors', such as triple-negative breast cancer (TNBC) and ovarian cancer.

ErVimmune recently announced the first closing of its Series A financing, successfully raising €17 million (approximately $19.8 million) from a consortium of international investors, which includes existing shareholder Seventure Partners and new investor SPRIM Global Investments. This funding is intended to propel the clinical development of ErVac01, a heterologous vaccine designed to generate a broad immune response across diverse patient populations.

Industry Overview

France's biotechnology sector is a rapidly growing industry, underpinned by robust government support and extensive research infrastructure. The country has become a European hub for life sciences, boasting a vibrant ecosystem of star